Skip to content

Comprehensive Diabetes Guideline Review and Device Workshop

Type 2 diabetes mellitus (T2DM) accounts for up to 95% of diagnosed cases in adults. Treatment recommendations from the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) and the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) focus on individualized care that is more aggressive in earlier stages of disease. This session will update the audience of the current evidence-based guidelines for the management of type 2 diabetes, and review currently available treatments and mechanisms of delivery. .

Learning Objectives

Upon completion of this activity, the participant will be able to:

  • Review the current ADA guidelines for the management of type 2 diabetes to optimize outcomes in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), heart failure and chronic kidney disease.
  • Identify drug therapy options for patients with type 2 diabetes with consideration to avoiding hypoglycemia and weight gain and minimizing cost. 
  • Demonstrate appropriate injection and administration technique of multiple devices (e.g. insulins, GLP-1RAs, glucagon, and pen  needles) . 
  • Explain the value of continuous glucose monitor downloads and develop suggestions for medication adjustments. 


Jennifer Goldman, RPh, PharmD, CDE, BC-ADM, FCCP, has been a pharmacist for over 30 years and joined the faculty at MCPHS University in 1997. She received her BS in Pharmacy in 1990 and her Doctorate in Pharmacy in 1996, both from MCPHS University. She completed a residency with a focus in primary care at the Boston VA Medical Center in 1997 and is board certified in advanced diabetes management (BC-ADM) and is a certified diabetes educator (CDE). She is a fellow of the American College of Clinical Pharmacists (FCCP). She was clinical pharmacy faculty at Tufts University Family Residency Program from 1997 to 2011. Dr. Goldman is currently Professor of Pharmacy Practice and coordinates and teaches in various therapeutics courses in the pharmacy and physician assistant programs. She has maintained a practice in family and internal medicine with a focus in diabetes and cardiovascular disease since 1997. She practices at Well Life Medical in Peabody, MA. She is an academic preceptor for MCPHS University PharmD candidates and the academic fellowship preceptor for MCPHS University/Becton Dickinson fellows in diabetes care. She has served on various statewide and national organizational committees and boards. Her research interests are in the area of diabetes, cardiovascular disease and the scholarship of teaching with multiple publications and invited presentations in these areas.

Free for MCPHS alumni, faculty and staff. For all others the fee is $12.00.


ACPE logo

Release Date: 3/22/21
Expiration Date: 3/22/22
Contact Hours: 1.5
Universal Activity Number: 0026-0000-21-120-H01-P
Topic Category: Disease State Management/Drug Therapy


MCPHS University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 1.5 contact hours (.15 CEUs).

Requirements for Credit

In order to receive credit, the participant must review the entire presentation and complete the post-test and evaluation form. Upon completion participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.

Statement of Disclosure

MCPHS University adheres to the ACPE Standards regarding commercial support of continuing pharmacy education. It is the policy of MCPHS University that the speakers and planning committee disclose real or apparent conflicts of interest relating to the topics of the educational activity, that relevant conflicts of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drugs or devices during their presentation.

No funding from industry provided for this event. No exhibitors will be present.
Jennifer Goldman, PharmD holds the relevant financial relationship with ineligible companies.
Speaker’s bureau: Amarin, Lilly, Novo Nordisk, Sanofi, Xeris
Consultant: Becton Dickenson
All CE staff members have no relevant financial relationships to disclose.